Daxor Corporation (NASDAQ:DXR) Short Interest Update
by Tristan Rich · The Markets DailyDaxor Corporation (NASDAQ:DXR – Get Free Report) was the target of a significant growth in short interest in August. As of August 31st, there was short interest totaling 592 shares, a growth of 93.5% from the August 15th total of 306 shares. Based on an average daily trading volume, of 3,474 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.0% of the shares of the stock are short sold.
Daxor Price Performance
Shares of DXR stock traded up $0.57 during trading hours on Wednesday, reaching $11.72. The company had a trading volume of 201,085 shares, compared to its average volume of 10,860. Daxor has a 12-month low of $8.56 and a 12-month high of $14.76. The stock has a fifty day moving average of $10.46 and a 200-day moving average of $10.42.
Institutional Trading of Daxor
Hedge funds and other institutional investors have recently modified their holdings of the stock. Crescent Grove Advisors LLC acquired a new position in shares of Daxor during the 1st quarter valued at about $104,000. Nano Cap New Millennium Growth Fund L P purchased a new stake in shares of Daxor in the fourth quarter valued at about $184,000. Susquehanna International Group LLP increased its position in Daxor by 97.7% during the second quarter. Susquehanna International Group LLP now owns 27,131 shares of the company’s stock worth $275,000 after purchasing an additional 13,411 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management purchased a new position in Daxor during the first quarter worth about $245,000. Finally, Aristides Capital LLC purchased a new position in Daxor during the first quarter worth about $403,000. 1.34% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
Separately, Weiss Ratings reissued a “hold (c)” rating on shares of Daxor in a research note on Wednesday, June 24th. One investment analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy”.
View Our Latest Analysis on DXR
About Daxor
Daxor Corporation is a medical device company that develops and commercializes diagnostic technologies for measuring blood volume. Its primary product is the BVA-100 Blood Volume Analyzer, which uses an automated tracer-dilution technique to measure a patient’s total blood volume, red blood cell volume and plasma volume.
The BVA-100 is designed to support clinical assessment and management in areas such as heart failure, critical care, blood disorders and other conditions in which a patient’s fluid or blood-volume status is important.